Amicus Therapeutics Inc

Amicus Therapeutics — Q3 2024 Earnings Presentation

23 slides from Amicus Therapeutics's earnings presentation, Nov 6, 2024

  1. Slide 1: 3Q24 Results Conference Call & Webcast

    AT T H E F O R E F R O N T O F THERAPIES FOR RARE DISEASES 3Q24 Results Conference Call & Webcast November 6, 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c

  3. Slide 3: A Rare Company

    A Rare Company A leading biotech company projected to deliver 2024 total revenue growth of 30%-32%1 LEVERAGEABLE GLOBAL 2 World-Class Clinical $69M-$71M COMMERCIAL APPROVED Development FY 2024 ORGANIZATION THERAPIES Capabilities Pombiliti + Opfolda Revenue1 ~500 EMPLOYEES 16-18% Guiding to Full Comb

  4. Slide 4: Strategic Priorities

    2024 Strategic 1 Galafold® revenue growth of 11-16% at CER1, now raised to 16-18% Priorities A Transformative 2 ® Execute multiple successful launches of Pombiliti + Opfolda ® Year Ahead for Amicus Advance ongoing studies to support medical and scientific 3 leadership in Fabry and Pompe diseases 4 A

  5. Slide 5: Galafold Continued Growth

    Galafold ® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5

  6. Slide 6: 2024 Galafold Success (as of September 30, 2024)

    2024 Galafold Success (as of September 30, 2024) Galafold is the only approved oral treatment option in Fabry disease A unique mechanism of action for Fabry patients with amenable variants $120.4M 3Q24 Galafold Revenue >60% 16-18% Share of Treated 2024 Galafold Amenable Patients Growth at CER1 2,400

  7. Slide 7: Galafold Performance

    Galafold Performance Q3 2024 Galafold reported revenue of $120.4M (+19% growth at CER) $450M-$458M1 $388M $329M Q4 $306M  Global mix of switch (~40%) and previously $107M $261M Q3 $120M untreated patients (~60%)2 Q3 $101M $182M  Expect non-linear quarterly growth to continue Q2 Q2 $111M due to une

  8. Slide 8: Key Growth Drivers for 2024

    Key Growth Drivers for 2024 Highest patient demand in last four years lays strong foundation for continued double-digit Galafold growth in 2024  Expanding market through uptake in naïve population as well as geographic and label expansion  Increasing patient identification through ongoing medical

  9. Slide 9: Pombiliti + Opfolda

    Pombiliti® (cipaglucosidase alfa-atga) + ® Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 9

  10. Slide 10: Pombiliti + Opfolda Performance

    Pombiliti + Opfolda Performance Pombiliti + Opfolda continues to build momentum with Q3 2024 revenue of $21.1M, up +33% from Q2 $69M-$71M1 Q3 $21M Q2 $16M $11M Q1 $11M FY23 FY24 Guiding to $69M-$71M in FY 2024 Pombiliti + Opfolda Revenue at CER 10 1At CER: Constant Exchange Rates

  11. Slide 11: Successful Global Launch of Pombiliti + Opfolda Underway

    Successful Global Launch of Pombiliti + Opfolda Underway Focus in 2024 is on maximizing the number of patients on therapy by year end Patient Demand KOL Outreach Access and As of end of October 2024 Reimbursement 203 patients have been Increasing depth and breadth of Positive interactions treated or

  12. Slide 12: Regulatory and Clinical Updates

    Regulatory and Clinical Updates Continuing to build the body of evidence and expand commercial access  >10 reimbursement dossiers and multiple regulatory submissions throughout 2024  Japan new drug application (JNDA) submitted to the Ministry of Health, Labor and Welfare (MHLW)  Ongoing clinical

  13. Slide 13: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 13

  14. Slide 14: Q3 2024 Select Financial Results

    Q3 2024 Select Financial Results Q3 2024 revenue of $141.5M, up 37% and non-GAAP net income of $30.8M Q3’24 YTD’24 (in thousands, except per share data) Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 GAAP net product sales $ 141,517 $ 103,501 $ 378,589 $ 284,274 GAAP cost of goods sold 13,2

  15. Slide 15: Updated Full-Year 2024 Guidance

    Updated Full-Year 2024 Guidance Updated Guidance Previous Guidance Total Revenue Growth1 30% to 32% 26% to 31% Galafold Revenue Growth1 16% to 18% 14% to 18% Pombiliti + Opfolda Revenue1 $69M to $71M $62M to $67M Non-GAAP Operating Expense $340M to $350M $345M to $360M Guiding to full-year 2024 non-

  16. Slide 16: Positioned for Significant Value Creation in 2024

    Positioned for Significant Value Creation in 2024 Unlocking the value of two unique commercial therapies in sizeable and growing markets Delivering Clear line of Accelerating sight to full-year total revenue generating non-GAAP1 growth positive profitability cashflow 16 1 Non-GAAP Net (Loss) Income

  17. Slide 17: Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases

    Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases >350 Patients* >2,600 Patients* Many Thousands of Patients* YE17 YE23 2024+ 17 *Clinical and commercial, all figures approximate

  18. Slide 18: Appendix

    Amicus Therapeutics Appendix

  19. Slide 19: Appendix I

    | Appendix | Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) (Unaudited) Three Months Ended Nine Months Ended September 30. September 30, 2024 2023 2024 2023 Total operating expenses - as reported GAAP $ 106,579 $ 110,578 $ 331,577 $ 331,791 Research and develo

  20. Slide 20: Appendix II

    | Appendix II Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except share and per share amounts) GAAP net loss Share-based compensation Changes in fair value of contingent consideration payable Depreciation and amortization Loss on impairment of assets Restruc

  21. Slide 21: Environmental, Social, & Governance (ESG) Snapshot

    Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to drive Diversity, Equity, & Management sustainability with our partners by Inclusion (DEI) Address a rare genetic disease Committed to producing incorporating Programs we Pledge to support a more inclusive

  22. Slide 22: FX Sensitivity and Galafold Distribution of Quarterly Sales

    FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q3 2024: Currency Variances: Q3 2023 Q3 2024 YoY Variance USD/ EUR 1.088 1.099 1.0% Distribution of Galafold Revenue GBP 1.266 1.301 2.7% by Quarter over Past 5 Years: JPY 0.007 0.007 (2.9%) Q1 Q2 Q3 Q4 5 Year A

  23. Slide 23: Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises

    Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FA B R Y F R A N C H I S E Galafold® (migalastat) Fabry Genetic Medicines Next-Generation Chaperone POMPE FRANCHISE Pombiliti® (cipagluc

Amicus Therapeutics — Q3 2024 Earnings Presentation on 6ix